Corvus Pharmaceuticals CRVS Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's pre-tax income?
- Corvus Pharmaceuticals (CRVS) reported pre-tax income of -$13.09M in Q1 2026.
- How has Corvus Pharmaceuticals's pre-tax income changed year-over-year?
- Corvus Pharmaceuticals's pre-tax income decreased by 183.2% year-over-year, from $15.73M to -$13.09M.
- What is the long-term trend for Corvus Pharmaceuticals's pre-tax income?
- Over 3 years (2022 to 2025), Corvus Pharmaceuticals's pre-tax income has grown at a -24.8% compound annual growth rate (CAGR), from -$31.3M to -$13.33M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.